Payment overview · 2025
General Payments
$4,411.02
113 reported records · 22 companies
Healthcare provider profile · identity verified
Ziad Berri, MD
Allopathic & Osteopathic Physicians|Internal Medicine · DEARBORN, MI · NPI 1881786770
Verified facts
What the public records show
CMS Open Payments records show Ziad Berri, MD received $4,411.02 in general payments during 2025 across 113 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Gemtesa, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 244 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Trelegy Ellipta by this doctor in 2024.
IRONWOOD PHARMACEUTICALS, INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Linzess as an associated drug or biological on 1209 records involving 1184 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Linzess by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 377 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $895.85 | 20.3% | 29 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $428.01 | 9.7% | 16 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $401.32 | 9.1% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $381.17 | 8.6% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $243.54 | 5.5% | 8 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $234.32 | 5.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $211.40 | 4.8% | 6 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $210.92 | 4.8% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $198.63 | 4.5% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $185.91 | 4.2% | 9 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $181.38 | 4.1% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $144.72 | 3.3% | 8 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $139.47 | 3.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $126.84 | 2.9% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $126.17 | 2.9% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $124.74 | 2.8% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $67.33 | 1.5% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.08 | 0.7% | 2 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.93 | 0.5% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.09 | 0.5% | 1 | 2025 |
| IRONWOOD PHARMACEUTICALS, INC | Unresolved — no canonical attribution shown | $18.18 | 0.4% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.02 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,411.02 | 113 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $407.17 | 8 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $401.32 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $332.13 | 11 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $325.70 | 4 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $234.32 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $220.21 | 11 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $198.63 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $181.38 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $144.95 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $137.32 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $126.84 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $126.17 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $124.74 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $122.41 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $98.41 | 6 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $98.41 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $89.74 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $89.74 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.90 | 5 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $69.41 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.97 | 4 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $55.47 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.96 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC., IRONWOOD PHARMACEUTICALS, INC | $35.24 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.08 | 2 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $20.93 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $20.09 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.02 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.25 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 244 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 49 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 377 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 199 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 89 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 100 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
199 | 38 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
21 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
244 | 45 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
377 | 60 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
185 | 31 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
100 | 21 |
| IRONWOOD PHARMACEUTICALS, INC Exact reporting entity; no affiliate inference |
2025 | Linzess open payments reported associated product |
CMS Open Payments — General Payments 1209 supporting records · 1184 recipient NPIs · example record 1227653589 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
199 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
377 | 60 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
41 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1209 | 194 |
| Omeprazole | Omeprazole | 941 | 147 |
| Losartan Potassium | Losartan Potassium | 834 | 128 |
| Metformin Hcl | Metformin Hcl | 722 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 701 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 496 | 92 |
| Diclofenac Sodium | Diclofenac Sodium | 495 | 122 |
| Pantoprazole Sodium | Pantoprazole Sodium | 485 | 92 |
| Simvastatin | Simvastatin | 378 | 53 |
| Jardiance | Empagliflozin | 377 | 60 |
| Tamsulosin Hcl | Tamsulosin Hcl | 359 | 64 |
| Ibuprofen | Ibuprofen | 306 | 93 |
| Lisinopril | Lisinopril | 296 | 54 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 43 |
| Azithromycin | Azithromycin | 266 | 154 |
| Clopidogrel | Clopidogrel Bisulfate | 260 | 45 |
| Hydralazine Hcl | Hydralazine Hcl | 258 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 245 | 60 |
| Farxiga | Dapagliflozin Propanediol | 244 | 45 |
| Famotidine | Famotidine | 243 | 46 |
| Allopurinol | Allopurinol | 239 | 32 |
| Alendronate Sodium | Alendronate Sodium | 232 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 229 | 43 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 210 | 55 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 207 | 30 |
| Linzess | Linaclotide | 199 | 38 |
| Furosemide | Furosemide | 196 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 189 | 38 |
| Eliquis | Apixaban | 185 | 31 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 185 | 64 |
| Celecoxib | Celecoxib | 182 | 52 |
| Meloxicam | Meloxicam | 176 | 46 |
| Ozempic | Semaglutide | 169 | 31 |
| Metformin Hcl Er | Metformin Hcl | 167 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 160 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 159 | 31 |
| Tradjenta | Linagliptin | 156 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 154 | 25 |
| Myrbetriq | Mirabegron | 153 | 31 |
| Gabapentin | Gabapentin | 147 | 33 |
| Pregabalin | Pregabalin | 147 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 144 | 67 |
| Donepezil Hcl | Donepezil Hcl | 140 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 137 | 14 |
| Promethazine Hcl | Promethazine Hcl | 129 | 82 |
| Ezetimibe | Ezetimibe | 127 | 20 |
| Meclizine Hcl | Meclizine Hcl | 123 | 40 |
| Januvia | Sitagliptin Phosphate | 118 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 118 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 117 | 37 |
| Potassium Chloride | Potassium Chloride | 113 | 22 |
| Ondansetron Hcl | Ondansetron Hcl | 101 | 39 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 100 | 78 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 100 | 21 |
| Glipizide Er | Glipizide | 98 | 21 |
| Hydrocortisone | Hydrocortisone | 97 | 21 |
| Alprazolam | Alprazolam | 96 | 18 |
| Bumetanide | Bumetanide | 96 | 17 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 93 | 21 |
| Carvedilol | Carvedilol | 89 | 16 |
| Mounjaro | Tirzepatide | 89 | 16 |
| Trazodone Hcl | Trazodone Hcl | 88 | 22 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 87 | 19 |
| Amoxicillin | Amoxicillin | 85 | 59 |
| Sertraline Hcl | Sertraline Hcl | 81 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 17 |
| Ammonium Lactate | Ammonium Lactate | 76 | 21 |
| Azelastine Hcl | Azelastine Hcl | 76 | 42 |
| Naproxen | Naproxen | 75 | 21 |
| Clonidine Hcl | Clonidine Hcl | 71 | 12 |
| Nifedipine Er | Nifedipine | 71 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 70 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 70 | 17 |
| Finasteride | Finasteride | 64 | 13 |
| Xarelto | Rivaroxaban | 63 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | suppressed |
| Lidocaine | Lidocaine | 60 | 15 |
| Prednisone | Prednisone | 60 | 44 |
| Glimepiride | Glimepiride | 59 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 13 |
| Procto-Med Hc | Hydrocortisone | 58 | 21 |
| Ketoconazole | Ketoconazole | 56 | 20 |
| Calcitriol | Calcitriol | 55 | 15 |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 53 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 50 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 50 | suppressed |
| Gemtesa | Vibegron | 49 | 13 |
| Rybelsus | Semaglutide | 48 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 47 | 12 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 47 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 47 | 11 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 44 | 13 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 43 | suppressed |
| Mupirocin | Mupirocin | 43 | 28 |
| Atenolol | Atenolol | 42 | suppressed |
| Loperamide | Loperamide Hcl | 42 | 19 |
| Colchicine | Colchicine | 41 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 41 | suppressed |
| Trulicity | Dulaglutide | 41 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 31 |
| Montelukast Sodium | Montelukast Sodium | 39 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 36 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | suppressed |
| Lorazepam | Lorazepam | 34 | suppressed |
| Methocarbamol | Methocarbamol | 34 | 18 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 34 | 25 |
| Cephalexin | Cephalexin | 33 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 33 | suppressed |
| Mirtazapine | Mirtazapine | 33 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 32 | 14 |
| Latanoprost | Latanoprost | 31 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 31 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 31 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | suppressed |
| Glipizide | Glipizide | 30 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 30 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 29 | 18 |
| Nystatin | Nystatin | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Topiramate | Topiramate | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 28 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Kerendia | Finerenone | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 26 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 25 | 13 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 25 | suppressed |
| Irbesartan | Irbesartan | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 23 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 23 | 18 |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 23 | 20 |
| Propranolol Hcl | Propranolol Hcl | 23 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 16 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Ibu | Ibuprofen | 21 | 11 |
| Methimazole | Methimazole | 21 | suppressed |
| Prolia | Denosumab | 21 | 13 |
| Spironolactone | Spironolactone | 21 | suppressed |
| Dexamethasone | Dexamethasone | 20 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 19 | suppressed |
| Proctozone-Hc | Hydrocortisone | 19 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 12 |
| Restasis | Cyclosporine | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 12 |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 17 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 17 | suppressed |
| Digoxin | Digoxin | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Indapamide | Indapamide | 16 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 16 | suppressed |
| Metronidazole | Metronidazole | 16 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 15 |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 13 | suppressed |
| Letrozole | Letrozole | 13 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Aripiprazole | Aripiprazole | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cialis | Tadalafil | 12 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Aricept | Donepezil Hcl | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,411.02 · 113 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, AREXVY, Auvelity, BREZTRI, CAPLYTA, COBENFY, CeQur Simplicity, Cologuard Collection Kit, EVENITY, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, JARDIANCE, Kerendia, LINZESS, MOUNJARO, MYFEMBREE, NEXLETOL, OTEZLA, Ozempic, REPATHA, REXULTI, SHINGRIX, Symbravo, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, VOQUEZNA, VRAYLAR, Wegovy, XIFAXAN, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error